Mode
Text Size
Log in / Sign up
N/A N=250 Randomized Treatment

Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media

Acute Otitis Media

Enrolled (actual)
250
Serious AEs
4.0%
Results posted
Dec 2021
Primary outcome: Primary: The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year — 1.48; 1.56 Occurrences per child-year — p=0.66

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Tympanostomy tube placement (Device); Amoxicillin-Clavulanate and/or Ceftriaxone (Drug); Ofloxacin Otic (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Alejandro Hoberman
Primary completion
Mar 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year
1.48; 1.56 0.66
SECONDARY
The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year According to the Estimated Risk of Acute Otitis Media (AOM) Recurrences at Enrollment
1.28; 1.56; 1.67; 1.56 0.08
SECONDARY
The Frequency Distribution of AOM Episodes Among Children Completing the Study
17; 12; 41; 41; 24; 29 0.48
SECONDARY
The Distribution of Children Experiencing Treatment Failure (TF)
56; 74; 68; 46
SECONDARY
The Time to the First Episode of AOM
4.34; 2.33
SECONDARY
The Distribution of AOM Episodes Categorized as Probably Severe or Probably Nonsevere
180; 168; 156; 165
SECONDARY
The Distribution of AOM Episodes Presenting With Tympanic Membrane Bulging or Otorrhea
86; 248; 250; 85
SECONDARY
The Mean Days Per Year Children Experience Tube Otorrhea
7.96; 2.83
SECONDARY
The Mean Days Per Year Children Experience AOM Symptoms With an Intact Tympanic Membrane (TM)
2.00; 8.33
SECONDARY
The Mean Days Per Year Children Receive Systemic Antimicrobials for AOM
8.76; 12.92
SECONDARY
The Distribution of Children for Whom Protocol-Defined Diarrhea (PDD) Was Reported
21; 34; 108; 87
SECONDARY
The Distribution of Children for Whom Diaper Dermatitis Was Reported
25; 33; 104; 88
SECONDARY
The Distribution of Children for Whom Tube Otorrhea Was Reported
94; 34; 35; 87
SECONDARY
The Distribution of Children With a Penicillin-Nonsusceptible Nasopharyngeal or Throat Isolate At Any Follow-up Visit According to the Colonization Status at Enrollment
25; 24; 12; 11; 22; 20
SECONDARY
The Distribution of Nonsusceptible Nasopharyngeal or Throat Pathogens Recovered at Episodes of AOM
66; 64; 107; 132
SECONDARY
The Distribution of Nonsusceptible Nasopharyngeal or Throat Pathogens Recovered at Routine Non-Illness Visits
116; 98; 369; 349
SECONDARY
The Distribution of Nonsusceptible Nasopharyngeal or Throat Pathogens Recovered at AOM Episodes Late During the Respiratory Season (April-May)
16; 16; 21; 27
SECONDARY
The Mean Score Representing Parental Satisfaction With Clinical Management
4.64; 4.43
SECONDARY
The Distribution of Parent Reports Indicating At Least One Health Care Encounter Since the Previous Study Visit as an Indicator of Medical Resource Use
738; 672; 897; 956
SECONDARY
The Distribution of Reported Occurrences of a Parent Missing Work Due to Child's Illness, as an Indicator of Non-Medical Resource Use
286; 256; 1317; 1342; 32; 30
SECONDARY
The Distribution of Reported Occurrences of the Need for Special Childcare Arrangements Due to Child's Illness, as an Indicator of Non-Medical Resource Use
231; 195; 1402; 1429; 2; 4
SECONDARY
The Mean Scores on the 6 Item Quality of Life Survey Questionnaire (OM-6)
1.5; 1.55; 8.45; 8.37
SECONDARY
The Mean Scores on the 6 Item Caregiver Impact Questionnaire (CIQ)
10.82; 10.93; 8.55; 8.50
SECONDARY
The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness
7.19; 5.79
SECONDARY
The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness According to the Estimated Risk of Acute Otitis Media Recurrences at Enrollment
6.25; 5.70; 8.00; 5.91

Summary

To determine whether tympanostomy tube placement (TTP) compared with nonsurgical management will meaningfully improve children's acute otitis media (AOM) experience over the succeeding 2 years.

Eligibility Criteria

Inclusion Criteria

  • are aged 6-35 months,
  • have rAOM, defined as the occurrence of 3 AOM episodes in 6 months or 4 episodes in 12 months with ≥1 episode in the preceding 6 months, and
  • 2 of these AOM episodes have been documented by trained study personnel.

Exclusion Criteria

  • have a history of TTP,
  • have a chronic illness (cystic fibrosis, neoplasm, juvenile diabetes, renal or hepatic insufficiency, immune dysfunction, malabsorption, inflammatory bowel disease, severe asthma requiring at least 4 courses of oral corticosteroids during the last 12 months),
  • are allergic to amoxicillin,
  • have a congenital anomaly that might increase the risk of recurrences (e.g., cleft palate, Down's syndrome),
  • have had otitis media effusion for at least 3 months in addition to rAOM, or
  • have sensorineural hearing loss.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02567825). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search